CN102036967B - 作为5-ht6拮抗剂的芳基磺酰基吡唑啉甲脒衍生物 - Google Patents

作为5-ht6拮抗剂的芳基磺酰基吡唑啉甲脒衍生物 Download PDF

Info

Publication number
CN102036967B
CN102036967B CN200980108113.0A CN200980108113A CN102036967B CN 102036967 B CN102036967 B CN 102036967B CN 200980108113 A CN200980108113 A CN 200980108113A CN 102036967 B CN102036967 B CN 102036967B
Authority
CN
China
Prior art keywords
compound
mixture
dihydro
dcm
ethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980108113.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102036967A (zh
Inventor
A·梵洛维金
W·I·伊维玛巴克
A·斯托伊特
A·A·M·仁辛克
J·雯霍斯特
M·A·W·范德纽特
M·德汉
C·G·克鲁斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Abbott Healthcare Products BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products BV filed Critical Abbott Healthcare Products BV
Publication of CN102036967A publication Critical patent/CN102036967A/zh
Application granted granted Critical
Publication of CN102036967B publication Critical patent/CN102036967B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200980108113.0A 2008-03-18 2009-03-17 作为5-ht6拮抗剂的芳基磺酰基吡唑啉甲脒衍生物 Expired - Fee Related CN102036967B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08152873.9 2008-03-18
EP08152873 2008-03-18
PCT/EP2009/053133 WO2009115515A1 (en) 2008-03-18 2009-03-17 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410233817.3A Division CN104003937A (zh) 2008-03-18 2009-03-17 作为5-ht6拮抗剂的芳基磺酰基吡唑啉甲脒衍生物

Publications (2)

Publication Number Publication Date
CN102036967A CN102036967A (zh) 2011-04-27
CN102036967B true CN102036967B (zh) 2014-10-15

Family

ID=39639064

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980108113.0A Expired - Fee Related CN102036967B (zh) 2008-03-18 2009-03-17 作为5-ht6拮抗剂的芳基磺酰基吡唑啉甲脒衍生物
CN201410233817.3A Pending CN104003937A (zh) 2008-03-18 2009-03-17 作为5-ht6拮抗剂的芳基磺酰基吡唑啉甲脒衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410233817.3A Pending CN104003937A (zh) 2008-03-18 2009-03-17 作为5-ht6拮抗剂的芳基磺酰基吡唑啉甲脒衍生物

Country Status (29)

Country Link
US (3) US8563723B2 (https=)
EP (2) EP2265589B1 (https=)
JP (1) JP5504252B2 (https=)
KR (1) KR101623357B1 (https=)
CN (2) CN102036967B (https=)
AR (1) AR070898A1 (https=)
AU (1) AU2009226956C1 (https=)
BR (1) BRPI0908738A8 (https=)
CA (1) CA2717922A1 (https=)
CO (1) CO6290679A2 (https=)
CR (1) CR11742A (https=)
DK (2) DK2610247T3 (https=)
DO (2) DOP2010000276A (https=)
EA (1) EA023176B1 (https=)
EC (1) ECSP10010476A (https=)
ES (2) ES2577867T3 (https=)
HK (1) HK1201823A1 (https=)
IL (1) IL207846A0 (https=)
MX (1) MX2010010299A (https=)
MY (1) MY155318A (https=)
NZ (1) NZ587743A (https=)
PH (1) PH12013502376A1 (https=)
PL (2) PL2610247T3 (https=)
PT (1) PT2610247T (https=)
SG (1) SG183688A1 (https=)
TW (1) TWI557110B (https=)
UA (1) UA105629C2 (https=)
WO (1) WO2009115515A1 (https=)
ZA (1) ZA201006272B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079935A1 (es) * 2010-01-29 2012-02-29 Abbott Healthcare Products Bv Sintesis de derivados de pirazolin carboxamidina sustituida
SI2744330T1 (sl) * 2011-08-15 2020-11-30 University Of Utah Research Foundation Substituirani (E)-N'-(1-feniletiliden) benzohidrazidni analogi kot inhibitorji histon-demetilaze
SG11201503562PA (en) * 2012-11-16 2015-06-29 Bristol Myers Squibb Co Dihydropyrazole gpr40 modulators
SG11201503556PA (en) 2012-11-16 2015-06-29 Bristol Myers Squibb Co Dihydropyrazole gpr40 modulators
RS55363B1 (sr) * 2012-11-16 2017-03-31 Bristol Myers Squibb Co Dihidropirazolni gpr40 modulatori
JP6762930B2 (ja) * 2014-05-09 2020-09-30 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ カンナビノイド受容体メディエータとしてのピラゾール誘導体およびそれらの使用
EP3180312B1 (en) 2014-08-12 2019-10-16 Loyola University Of Chicago Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same
EP3109237A1 (en) * 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
CN107460160A (zh) * 2017-08-23 2017-12-12 世贸天阶制药（江苏）有限责任公司 一种cho细胞无血清培养基
US10879709B2 (en) 2018-05-31 2020-12-29 National Taipei University Of Technology Power management system and operating method thereof
UY38911A (es) 2019-10-09 2021-05-31 Bayer Ag Compuestos de heteroarilo-triazol como pesticidas, formulaciones, usos y métodos de uso de los mismos
EP4178982A1 (en) 2020-07-13 2023-05-17 Precirix N.V. Antibody fragment against folr1
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1529595A (zh) * 2001-09-21 2004-09-15 ������ҩ�����޹�˾ 具有效cb1-拮抗活性的4,5-2氢-1h-吡唑衍生物
CN101072768A (zh) * 2004-10-07 2007-11-14 葛兰素集团有限公司 作为5－ht6受体拮抗剂用于治疗cns病症的5－磺酰基－1－哌啶基取代的吲哚衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR062907A1 (es) * 2006-09-22 2008-12-17 Solvay Pharm Bv Derivados de sulfonilpirazol y sulfonilpirazolincarboxamidina como antagonistas de 5-ht6

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1529595A (zh) * 2001-09-21 2004-09-15 ������ҩ�����޹�˾ 具有效cb1-拮抗活性的4,5-2氢-1h-吡唑衍生物
CN101072768A (zh) * 2004-10-07 2007-11-14 葛兰素集团有限公司 作为5－ht6受体拮抗剂用于治疗cns病症的5－磺酰基－1－哌啶基取代的吲哚衍生物

Also Published As

Publication number Publication date
KR101623357B1 (ko) 2016-05-23
US20110046171A1 (en) 2011-02-24
PL2265589T3 (pl) 2016-06-30
EP2265589B1 (en) 2016-01-27
EA201071083A1 (ru) 2011-04-29
SG183688A1 (en) 2012-09-27
EP2610247B1 (en) 2016-05-25
AR070898A1 (es) 2010-05-12
PT2610247T (pt) 2016-07-07
CO6290679A2 (es) 2011-06-20
PH12013502376B1 (en) 2015-01-12
IL207846A0 (en) 2010-12-30
EP2610247A1 (en) 2013-07-03
ES2577867T3 (es) 2016-07-19
AU2009226956C1 (en) 2014-03-06
ZA201006272B (en) 2011-05-25
DK2265589T3 (en) 2016-03-21
DOP2010000277A (es) 2011-01-31
US9126942B2 (en) 2015-09-08
MX2010010299A (es) 2010-12-15
PH12013502376A1 (en) 2015-01-12
US8901108B2 (en) 2014-12-02
CN104003937A (zh) 2014-08-27
US20150051239A1 (en) 2015-02-19
CN102036967A (zh) 2011-04-27
HK1152708A1 (en) 2012-03-09
CR11742A (es) 2011-03-03
UA105629C2 (uk) 2014-06-10
HK1201823A1 (en) 2015-09-11
BRPI0908738A2 (pt) 2017-06-13
TW200942519A (en) 2009-10-16
EP2265589A1 (en) 2010-12-29
CA2717922A1 (en) 2009-09-24
NZ587743A (en) 2012-06-29
ES2565184T3 (es) 2016-04-01
JP2011517443A (ja) 2011-06-09
ECSP10010476A (es) 2010-10-30
MY155318A (en) 2015-09-30
TWI557110B (zh) 2016-11-11
AU2009226956B2 (en) 2013-05-23
KR20100136504A (ko) 2010-12-28
DK2610247T3 (en) 2016-06-13
JP5504252B2 (ja) 2014-05-28
EA023176B1 (ru) 2016-05-31
BRPI0908738A8 (pt) 2017-10-10
AU2009226956A8 (en) 2010-09-23
WO2009115515A1 (en) 2009-09-24
AU2009226956A1 (en) 2009-09-24
DOP2010000276A (es) 2010-11-15
PL2610247T3 (pl) 2017-02-28
US20140011775A1 (en) 2014-01-09
US8563723B2 (en) 2013-10-22

Similar Documents

Publication Publication Date Title
CN102036967B (zh) 作为5-ht6拮抗剂的芳基磺酰基吡唑啉甲脒衍生物
CN114040914B (zh) 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
TW202115038A (zh) 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用
CN111440189B (zh) 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用
JP6800885B2 (ja) イミダゾピラジン及びピラゾロピリミジン、並びにａｍｐａ受容体調節物質としてのこれらの使用
CN106536491B (zh) 作为盐皮质激素受体调节剂的苯并噁嗪酮酰胺
AU2010297263B2 (en) Substituted N-phenyl-1-(4-pyridinyl)-1H-pyrazol-3-amines
CN114409656B (zh) Pim激酶抑制剂
UA74850C2 (en) Amide derivatives as nmda receptor antagonists
EA035544B1 (ru) Производные тетрагидроизохинолина
CN103539785A (zh) 大麻素受体调节剂
TW202333693A (zh) 苯并哌啶衍生物調節劑、其製備方法和應用
KR101905295B1 (ko) 나프티리딘디온 유도체
ES2960408T3 (es) Compuesto heterocíclico y su uso como modulador alostérico positivo del receptor M1 muscarínico colinérgico
ES3001126T3 (es) Derivados de 1-((1H-pirazol-4-il)metil)-3-(fenil)-1,3-dihidro-2H-imidazol-2-ona y compuestos relacionados como antagonistas de GPR139 para el tratamiento de la depresión
CN106414443B (zh) 吡啶并嘧啶二酮衍生物
BR112013005823B1 (pt) Compostos heterocíclicos para o tratamento ou prevenção de distúrbios causados pela neurotransmissão reduzida de serotonina, norefnefrina ou dopamina
WO2025061180A1 (zh) 含氮并环类化合物、其药物组合物及其应用
JP2018514543A (ja) インドロン化合物、及びａｍｐａ受容体調節因子としてのそれらの使用
TW202430510A (zh) 含哌啶多環類衍生物調節劑、其製備方法和應用
WO2023216753A1 (zh) 咪唑并哒嗪取代苯环类衍生物、制备方法、药物组合物及用途
CN118591536A (zh) Irak4抑制剂
RU2672725C2 (ru) Способ получения соединения
CN119080754A (zh) 作为α5-GABAA受体调节剂的杂环化合物及其用途
WO2026041138A1 (zh) 作为vav1降解剂的苯并杂环类化合物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1152708

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1152708

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141015

Termination date: 20170317